<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2809">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04358952</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/20/0117</org_study_id>
    <secondary_id>2020-A00852-37</secondary_id>
    <nct_id>NCT04358952</nct_id>
  </id_info>
  <brief_title>Myocardial Involvement of Severe Acute Respiratory Syndrome-Cov-2 (Covid19) Infected Patients</brief_title>
  <acronym>COCARDE</acronym>
  <official_title>Imaging Cardiac Phenotype of SARS-Cov-2 (Covid19) Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effects of severe acute respiratory syndrome SARS-Cov-2 (Covid-19) on the myocardium and
      their role in the clinical course of infected patients are still unknown. Epidemiological
      studies report biological myocardial involvement in 10 to 25% of cases. The objective of this
      study is to cardiac phenotype using comprehensive cardiac imaging tools of patients infected
      with Covid 19 in order to explore the functional impact of the infection on the myocardium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A large population of Covid 19 infected patients of different ages and severity levels will
      be explored by transthoracic echocardiography with measurement of myocardial functional
      parameters such as ejection fraction, longitudinal strain and relaxation parameters and will
      be compared to an uninfected population paired for age and sex.

      Patients with biological myocardial involvement will be followed to determine the evolution
      of their myocardial functional parameters during the course of the infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2020</start_date>
  <completion_date type="Anticipated">November 4, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 4, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular function</measure>
    <time_frame>Day 0</time_frame>
    <description>Left ventricular function evaluated by global longitudinal strain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular function</measure>
    <time_frame>Day 3</time_frame>
    <description>Left ventricular function evaluated by global longitudinal strain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular function</measure>
    <time_frame>Day 7</time_frame>
    <description>Left ventricular function evaluated by global longitudinal strain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>inflammatory biological parameters</measure>
    <time_frame>Day 0</time_frame>
    <description>Cytokine rate</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cardiomyopathies</condition>
  <arm_group>
    <arm_group_label>COVID + patients</arm_group_label>
    <description>Major patients hospitalized for respiratory criteria for SARS-Cov-2 infection confirmed by RT-PCR</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Global Longitudinal Strain</intervention_name>
    <description>Electrocardiogram with measure of the Global Longitudinal Strain to evaluate myocardiac dysfunction</description>
    <arm_group_label>COVID + patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Inflammatory cytokines
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Major patients hospitalized for respiratory criteria for SARS-Cov-2 infection confirmed by
        RT-PCR
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major patients hospitalized for respiratory criteria for SARS-Cov-2 infection
             confirmed by RT-PCR

        Exclusion Criteria:

          -  Underage patients. Patients refusing to participate in research. Patients with a
             history of heart disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent MINVILLE, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent MINVILLE, PU-PH</last_name>
    <phone>33 5 61 32 27 91</phone>
    <phone_ext>+33</phone_ext>
    <email>Minville.v@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier LAIREZ, PU-PH</last_name>
    <phone>0561322873</phone>
    <phone_ext>+33</phone_ext>
    <email>lairez.o@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UHToulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent MINVILLE, PU PH</last_name>
      <phone>33 5 61 32 27 91</phone>
      <email>minville.v@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Left ventricular systolic function</keyword>
  <keyword>left ventricular diastolic function</keyword>
  <keyword>global longitudinal strain</keyword>
  <keyword>SARS-Cov-2</keyword>
  <keyword>Covid-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

